Compare Koninklijke Philips NV (PHG) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Koninklijke Philips NV vs TransMedics Group Inc — how do they compare? Koninklijke Philips NV trades at $25.02 (market cap $24.61B), while TransMedics Group Inc trades at $86.5 (market cap $3.00B). The key difference: Koninklijke Philips NV is far larger — about 8.2× TransMedics Group Inc's market cap, and Koninklijke Philips NV pays a 4.05% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| PHG | TMDX | |
|---|---|---|
Market Cap | $24.61B | $3.00B |
Sector | Health | Technology |
52-Week High | $32.91 | $150.42 |
52-Week Low | $25.02 | $61.99 |
Enterprise Value | $31.21B | $3.39B |
Dividend Yield | 4.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PHG trades at $25.29, down 2.32% today, with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with Q2 2026 EPS of $0.57 beating expectations of $0.40, and positive net income of $895M in 2025 reversing previous losses. Recent product launches in women's health and AI-powered medical devices demonstrate innovation momentum.
The outlook is mixed with strong fundamentals and analyst support (36% buy ratings) offset by technical weakness. Key opportunities include margin expansion and new product adoption, while risks involve cybersecurity threats and competitive pressures in healthcare technology.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings performance. The company reported strong 2025 results with $605M revenue and 31.4% net margin, though 2026 projections show margin compression. Recent news highlights growth initiatives in kidney transplantation and European markets, alongside ongoing legal investigations into fiduciary duties.
The stock offers upside to the $99.57 consensus price target, supported by analyst bullishness (69% buy ratings), but faces risks from margin pressure, legal scrutiny, and earnings misses. Revenue growth remains a key catalyst, though execution risks and investor sentiment headwinds warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
